Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Collaborators (365)

Home PD, Beck-Nielsen H, Cobitz AR, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, Pocock SJ, Campbell I, Ford I, Hildebrandt P, Landgraf R, Verheugt F, Komajda M, Böhm M, Gavazzi A, Lees K, Marre M, Ponikowski P, Syvänne M, Jerums G, Lang A, Watts R, De Looze F, Naidu V, Moses R, Heazlewood V, McKeirnan M, Lowy A, Roberts T, Weber E, Coucke F, Tits J, Keymeulen B, Giri M, Mortelmans J, Hutsebaut A, Denier W, Borissova A, Ovcharova N, Hristov V, Veleva N, Koeva L, Mitkov M, Rusev T, Daskalova I, Metelko Z, Rotvik VZ, Goldoni V, Jandric-Balen M, Rubes J, Beer Z, Aganovic I, Erzen DJ, Janousek J, Saudek F, Valentova E, Honka M, Sobeslavská V, Mandakova E, Belobradkova J, Skala P, Weiner P, Komrskova M, Dohnalova L, Juhl H, Kolendorf K, Larsen S, Lervang HH, Prange A, Ørskov L, Torsteinsson B, Storm T, Perrild H, Kork A, Tupits H, Kunder M, Viitas L, Toomsoo T, Vides H, Adojaan B, Last I, Veidrik K, Lanno R, Arbeiter K, Stern M, Eriksson J, Hopsu J, Siren R, Sulosaari S, Piippo T, Saltevo J, Latva-Nevala A, Kaitila T, Jarvinen P, Piiroinen A, Pirttiaho H, Himanen P, Ilvesmaki V, Juurinen L, Siren R, Pietilä M, Ruotsalainen S, Verier-Mine O, Brun J, Charpentier G, Le Devehat C, Picard C, Verlet E, Triot P, Fonteny R, Quadrelli J, Poisson P, Fournier P, Vogel JY, Decloux O, Goepfert L, Ruetsch M, Huberschwiller JL, Gissler M, Michalak B, Obadia D, Bourgoin M, Cadinot D, Jouin C, Sacareau D, Bismuth M, Coeure T, Fabie C, Reinard JF, Poinot P, Galy P, Vilarem H, Binet G, Gay B, Munck P, Ott P, Nauck M, Paschke R, Frick H, Sammler A, Morcos M, Stuermer W, Segiet T, Schaffstein W, Berek U, Schaffert A, Raddatz C, Ayasse D, Naumann R, Scholz G, Kirrbach P, Mueller O, Raptis S, Pagkalos E, Pappas S, Fragkoulia A, Katsilambros N, Melidonis A, Piaditis G, Zoupas C, Soulis K, Vagenakis A, Makriyannis D, Kaldrimidis P, Migdalis I, Baranyai M, Faludi P, Földesi I, Gachályi B, Dudas M, Hidvégi T, Juhász E, Kerényi Z, Neuwirth G, Oroszlán T, Pátkay J, Simon K, Szegedi J, Tamas G, Mészáros J, Vándorfi G, Voros P, Kurta G, Fossati C, Uccioli L, Pasquali R, Melchionda N, Parenti M, Galluzzo A, Carboni L, Giampietro O, Calderini MC, Giorgino R, Ambrosi B, Arcangeli A, Aiello A, Ghirlanda G, Gatti A, Valentini U, Pozzilli P, Caggiano D, Rezgale I, Kokare L, Andersone I, Vizina B, Teterovska D, Eglite A, Pirags V, Kudule L, Sturis I, Lagzdina I, Lasiene J, Pliuskys J, Jakuboniene N, Varanauskiene E, Urbonaite B, Butkus J, Gumbrevicius G, de Backer W, van de Walle V, Jonker J, Janssen M, Gulzar F, Ong I, Ferguson H, Feis W, Fransen H, Snijders J, Budumian M, Cutfield R, Scott R, Mann J, Smith B, Dissanayake A, Khant M, Leikis R, Dixon P, Kinalska I, Wierusz-Wysocka B, Semetkowska-Jurkiewicz E, Stankiewicz A, Zytkiewicz-Jaruga D, Polaszewska-Muszynska M, Jedynasty K, Szybinski Z, Jusiak K, Mikolajczyk-Swatko A, Bandurska-Stankiewicz E, Bojarska-Los M, Krzyzagorska E, Bochenek A, Lopatynski J, Szczecinska H, Kubalski P, Ionescu-Tirgoviste C, Hancu N, Serban V, Graur M, Mota M, Barnea A, Dobjansch C, Ametov A, Dreval A, Pheophanova S, Demidova I, Vorokhobina N, Subaeva L, Macko M, Fabry J, Buganova I, Fabryova L, Kalinova L, Dzuponova J, Krahulec B, Toserova E, Nemethyova Z, Vozar J, Gabrisova A, Tkac I, Okapcova J, Kupcova T, Nehajova E, Farkas P, Martinka E, Torres MM, Jimenez LE, Conget I, Pombo JH, Gaztambide S, Manzanares J, Serrano A, Vazquez C, Schönander M, Norrby A, Tengel R, Nilsson A, Lager I, Mathiessen U, Andersson PO, Adamsson U, Sjöberg F, Forbes E, Nicol L, Lindmark S, Aronsson D, Dahl M, Landin-Olsson M, Polhem B, Hellke P, Waller J, Zethelius B, Tronko M, Bodnar P, Larin O, Karachentsev Y, Pertseva T, Serhiyenko A, Prudius P, O'Hare P, Allamby P, Blagden M, Gumbley M, Gaunt R, Keating D, Maksimczyk P, Pimm M, Strawford I, Wall T, Matthews A, Sampson M, Adler A, Cahill T, Fox C, Ham J, Harrower A, Hole J, Rowlands S, Husselbee P, Downie F, Brodie R, McIntyre J, Hannah J, MacPhee S, Deighan J, MacNeill D, Duddy A, Murphy G, Murray S, Mishra A, Brandon D, Brydie D, Simpson J, Livingstone E, Dunlop T, Baksi A, Cowie A, Middleton A, Ryan J, Seaman A, Lee T, Adler L, Jones W, Leech N.

Author information

  • 1Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, UK. philip.home@newcastle.ac.uk

Abstract

BACKGROUND:

Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety.

METHODS:

In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1.20. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00379769.

FINDINGS:

321 people in the rosiglitazone group and 323 in the active control group experienced the primary outcome during a mean 5.5-year follow-up, meeting the criterion of non-inferiority (HR 0.99, 95% CI 0.85-1.16). HR was 0.84 (0.59-1.18) for cardiovascular death, 1.14 (0.80-1.63) for myocardial infarction, and 0.72 (0.49-1.06) for stroke. Heart failure causing admission to hospital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2.10, 1.35-3.27, risk difference per 1000 person-years 2.6, 1.1-4.1). Upper and distal lower limb fracture rates were increased mainly in women randomly assigned to rosiglitazone. Mean HbA(1c) was lower in the rosiglitazone group than in the control group at 5 years.

INTERPRETATION:

Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.

FUNDING:

GlaxoSmithKline plc, UK.

Comment in

PMID:
19501900
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk